February 8, 2024
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
January 8, 2024
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
January 3, 2024
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
December 12, 2023
Athira Pharma Announces Encouraging Results from SHAPE Phase 2 Clinical Trial of Fosgonimeton for the Treatment of Parkinson's Disease Dementia and Dementia with Lewy Bodies
November 29, 2023
Athira Pharma to Participate in Sidoti December Small Cap Investor Conference
November 28, 2023
Athira Pharma Announces Upcoming Presentation at Motor Neurone Disease Association’s 34ᵗʰ International Symposium on ALS/MND
November 15, 2023
Athira Pharma Presents Preclinical Data Highlighting Fosgonimeton’s Neuroprotective Effects Against Amyloid-β-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer’s Disease
November 9, 2023
Athira Pharma Reports Third Quarter 2023 Financial Results and Pipeline and Business Updates
November 8, 2023
Athira Pharma to Participate in Jefferies London Healthcare Conference
October 5, 2023
Athira Pharma Presents Preclinical Data Further Supporting the Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
Displaying 31 - 40 of 150